FrancophonIA/ELRC3.0 huggingface dataset:
English: Now turn over for information on how to use your pre-filled pen.
Danish: Vend indlægssedlen for at få oplysninger om, hvordan du skal bruge den fyldte pen.
English: • Keep the needle in your skin after the dose counter has returned to 0
Danish: • Lad nålen forblive under huden, efter dosistælleren er vendt tilbage på 0, og tæl langsomt til 6.
English: You should stop your GLP-1 treatment prior to starting on Xultophy.
Danish: Du skal stoppe behandlingen med GLP-1-analogen, før du begynder at bruge Xultophy.
English: When transferring from a GLP-1 receptor agonist, the recommended starting dose of Xultophy is 16 dose steps (16 units insulin degludec and 0.6 mg liraglutide) (see section 5.1).
Danish: Ved skift fra en GLP-1 receptoragonist er den anbefalede startdosis af Xultophy 16 dosistrin (16 enheder insulin degludec og 0,6 mg liraglutid) (se pkt.
English: Your pen is a pre-filled dial-a-dose pen.
Danish: Pennen er en fyldt pen med dosisindstilling.
English: For study results with respect to combinations, effects on glycaemic control, and the populations studied, see sections 4.4, 4.5 and 5.1.
Danish: For forsøgsresultater vedrørende kombinationer, virkning på glykæmisk kontrol og de undersøgte populationer henvises til pkt.
English: One pre-filled pen contains 3 mL equivalent to 300 units insulin degludec and 10.8 mg liraglutide.
Danish: En fyldt pen indeholder 3 ml svarende til 300 enheder insulin degludec og 10,8 mg liraglutid.
English: Add on to sulfonylurea ± metformin
Danish: Supplement til sulfonylurinstof ± pioglitazon
English: Figure 2 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or in combination with metformin
Danish: Figur 2 Gennemsnitlig HbA1c (%) efter behandlingsuge hos patienter med type 2-diabetes mellitus, der var utilstrækkeligt kontrolleret på sulfonylurinstof alene eller i kombination med metformin
English: • The maximum daily dose of Xultophy is 50 dose steps (50 units of insulin degludec and 1.8 mg of liraglutide).
Danish: • Den maksimale daglige dosis Xultophy er 50 dosistrin (50 enheder insulin degludec og 1,8 mg liraglutid).
English: Non-fatal MI
Danish: Ikke-fatal apopleksi Ikke-fatal MI
English: Flushed, dry skin, feeling sleepy or tired, dry mouth, fruity (acetone) breath, urinating more often, feeling thirsty, losing your appetite, feeling or being sick (nausea or vomiting).
Danish: Rødme, tør hud, døsighed eller træthed, mundtørhed, frugtagtig (acetonelugtende) ånde, hyppigere vandladning, tørst, nedsat appetit, kvalme eller opkastning.
English: If you use more Xultophy than you should, your blood sugar may get low (hypoglycaemia) or you may feel or be sick (nausea or vomiting).
Danish: Hvis du bruger mere Xultophy, end du skal, kan dit blodsukker blive lavt (hypoglykæmi), eller du kan få kvalme eller kaste op. Se informationen under punkt 4 "Lavt blodsukker (hypoglykæmi)", hvis dit blodsukker bliver lavt.
English: • Xultophy is administered as ‘dose steps'.
Danish: • Xultophy indgives som "dosistrin".
English: Xultophy (dose steps)
Danish: Xultophy (dosistrin)
English: There is no clinical experience with the use of Xultophy during breast-feeding.
Danish: Der foreligger ingen kliniske erfaringer med anvendelsen af Xultophy under amning.
English: Baseline→End of trial
Danish: Baseline→Studiets afsl.
English: No cardiovascular outcomes trials have been performed with Xultophy.
Danish: Der er ikke udført studier med kardiovaskulære endepunkter for Xultophy.
English: You should stop your basal insulin treatment prior to starting on Xultophy.
Danish: Du skal stoppe behandlingen med basalinsulin, før du begynder at bruge Xultophy.
English: • thyroid hormones - for thyroid disease
Danish: • skjoldbruskkirtelhormoner - mod sygdom i skjoldbruskkirtlen
English: The dose counter shows the dose in dose steps.
Danish: Dosistælleren viser dosis i dosistrin.
English: The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.00 (0 patients out of 278) for Xultophy and 0.01 (1 patient out of 279) for insulin glargine.
Danish: Andelen af alvorlig hypoglykæmi pr. patienteksponeringsår (procentdel af patienter) var 0,00 (0 patienter ud af 278) for Xultophy og 0,01 (1 patient ud af 279) for insulin glargin.
English: Each mL of solution contains 100 units of insulin degludec and 3.6 mg liraglutide.
Danish: Hver ml opløsning indeholder 100 enheder insulin degludec og 3,6 mg liraglutid.
English: The maximum daily dose of Xultophy is 50 dose steps (50 units insulin degludec and 1.8 mg liraglutide).
Danish: Den maksimale daglige dosis Xultophy er 50 dosistrin (50 enheder insulin degludec og 1,8 mg liraglutid).
English: Always watch the dose counter to know how many dose steps you inject.
Danish: Hold altid øje med dosistælleren, så du ved, hvor mange dosistrin,
English: Novo Allé, Bagsværd, 2880, Denmark
Danish: Novo Allé, DK-2880 Bagsværd, Danmark
English: When transferring from basal insulin therapy, the recommended starting dose of Xultophy is 16 dose steps (16 units insulin degludec and 0.6 mg liraglutide) (see section 4.4 and 5.1).
Danish: Ved skift fra behandling med basalinsulin er den anbefalede startdosis af Xultophy 16 dosistrin (16 enheder insulin degludec og 0,6 mg liraglutid) (se pkt.
English: Package leaflet: Information for the patient Xultophy 100 units/mL + 3.6 mg/mL solution for injection insulin degludec + liraglutide
Danish: Indlægsseddel: Information til patienten Xultophy 100 enheder/ml + 3,6 mg/ml injektionsvæske, opløsning insulin degludec + liraglutid
English: Insulin degludec Liraglutide
Danish: Xultophy Insulin degludec Liraglutid
English: Xultophy cannot be recommended for use in patients with end-stage renal disease (see sections 5.1 and 5.2).
Danish: Xultophy kan ikke anbefales til patienter med terminal nyreinsufficiens (se pkt.
English: The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia defined as an episode requiring assistance of another person was 0.01 (2 patients out of 825) for Xultophy, 0.01 (2 patients out of 412) for insulin degludec and 0.00 (0 patients out of 412) for liraglutide.
Danish: Raten af bekræftet hypoglykæmi var lavere med Xultophy end med insulin degludec uanset den glykæmiske kontrol, se figur 1.Raten pr. patienteksponeringsår (procentdel af patienterne) for alvorlig hypoglykæmi defineret som en episode, der kræver hjælp fra en anden person, var 0,01 (2 patienter ud af 825) for Xultophy, 0,01 (2 patienter ud af 412) for insulin degludec og 0,00 (0 patienter ud af 412) for liraglutid.
English: Xultophy is a pre-filled dial-a-dose pen.
Danish: Xultophy er en fyldt pen med dosisindstilling.
English: Figure 3 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on GLP-1 receptor agonists
Danish: Figur 3 Gennemsnitlig HbA1c (%) efter behandlingsuge hos patienter med type 2-diabetes mellitus, der var utilstrækkeligt kontrolleret med GLP-1-receptoragonister
English: Always make sure that a drop appears at the needle tip before you inject.
Danish: Kontrollér altid, at der kommer en dråbe til syne ved nålespidsen,
English: The key results of the trial are listed in Figure 5 and Table 5.
Danish: De vigtigste resultater fra studiet er vist i figur 5 og tabel 5.
English: The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.01 (1 patient out of 199) for Xultophy and 0.00 (0 patients out of 199) for insulin degludec.
Danish: Andelen af alvorlig hypoglykæmi pr. patienteksponeringsår (procentdel af patienter) var 0,01 (1 patient ud af 199) for Xultophy og 0,00 (0 patienter ud af 199) for insulin degludec.
English: How to use Xultophy
Danish: Sådan skal du bruge Xultophy
English: How Xultophy works
Danish: Sådan virker Xultophy
English: The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.01 (1 patient out of 291) for Xultophy and 0.00 (0 patients out of 199) for GLP-1 receptor agonists.
Danish: Andelen af patienter med alvorlig hypoglykæmi pr. patienteksponeringsår (procentdel af patienter) var 0,01 (1 patient ud af 291) for Xultophy og 0,00 (0 patienter ud af 199) for GLP-1-receptoragonister.
English: • Turn the dose selector to select 2 dose steps.
Danish: • Indstil dosisvælgeren på 2 dosistrin.
English: Xultophy 100 units/mL + 3.6 mg/mL solution for injection insulin degludec + liraglutide SC use
Danish: Xultophy 100 enheder/ml + 3,6 mg/ml injektionsvæske, opløsning insulin degludec + liraglutid s.c. anvendelse
English: Figure 4 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on insulin glargine
Danish: Figur 4 Gennemsnitlig HbA1c (%) efter behandlingsuge hos patienter med type 2-diabetes mellitus, der var utilstrækkeligt kontrolleret med insulin glargin
English: • If you have any further questions, ask your doctor, pharmacist or nurse.
Danish: Er du i tvivl, så spørg lægen, apotekspersonalet eller sygeplejersken.
English: Solution for injection.
Danish: du injicerer.
English: 1 mL solution contains 100 units insulin degludec* and 3.6 mg liraglutide*.
Danish: 1 ml opløsning indeholder 100 enheder insulin degludec* og 3,6 mg liraglutid*.
English: Favours insulin glargine
Danish: Til fordel for insulin glargin
English: One dose step contains 1 unit insulin degludec + 0.036 mg liraglutide.
Danish: Ét dosistrin indeholder 1 enhed insulin degludec + 0,036 mg liraglutid.
English: Thyroid adverse events
Danish: Thyreoidea-relaterede bivirkninger
English: Approx. how much solution is left
Danish: Ca. så meget opløsning tilbage
English: Figure 5 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on basal insulin
Danish: Figur 5 Gennemsnitlig HbA1c (%) efter behandlingsuge hos patienter med type 2-diabetes mellitus, der var utilstrækkeligt kontrolleret på basalinsulin
English: In animal studies, peripheral administration of liraglutide led to uptake in specific brain regions involved in regulation of appetite, where liraglutide, via specific activation of the GLP1R, increased key satiety and decreased key hunger signals, thereby leading to lower body weight.
Danish: I dyreforsøg førte perifer administration (i ekstremitet) af liraglutid til optagelse i specifikke hjerneregioner involveret i appetitreguleringen.
English: • Inflamed gallbladder.
Danish: • Betændelse i galdeblæren.
English: Xultophy 100 units/mL + 3.6 mg/mL solution for injection.
Danish: Xultophy 100 enheder/ml + 3,6 mg/ml injektionsvæske, opløsning.
English: For detailed instructions for use, see the package leaflet.
Danish: Se detaljeret brugervejledning på indlægssedlen.
English: Very common Hypoglycaemia Common
Danish: Ikke almindelig Cholelithiasis Ikke almindelig Cholecystitis
English: Favours insulin degludec
Danish: Til fordel for insulin degludec
English: Liraglutide did not change the overall exposure of griseofulvin following administration of a single dose of griseofulvin 500 mg. Griseofulvin Cmax increased by 37% while median tmax did not change.
Danish: Liraglutid ændrede ikke den overordnede eksponering for griseofulvin efter administration af én enkelt dosis på 500 mg griseofulvin.
English: • One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide.
Danish: • Ét dosistrin indeholder 1 enhed insulin degludec og 0,036 mg liraglutid.
English: Xultophy is administered as ‘dose steps'.
Danish: Xultophy indgives som "dosistrin".
English: Urticaria
Danish: IDeg
English: Placebo N
Danish: Placebo
English: The key results of the trial are listed in Figure 2 and Table 3.
Danish: De vigtigste resultater fra studiet er vist i figur 2 og tabel 3.
English: The key results of the trial are listed in Figure 1 and Table 3.
Danish: De vigtigste resultater fra studiet er vist i figur 1 og tabel 3.
English: Xultophy 100 units/mL + 3.6 mg/mL solution for injection insulin degludec + liraglutide
Danish: Xultophy 100 enheder/ml + 3,6 mg/ml injektionsvæske, opløsning insulin degludec + liraglutid
English: Transfer from GLP-1 receptor agonist
Danish: Skift fra GLP-1-receptoragonist
English: After first opening: Store at a maximum of 30°C or store in a refrigerator Keep the cap on the pen to protect from light
Danish: Kan også opbevares i køleskab Opbevar pennen med hætten påsat for at beskytte mod lys
English: The key results of the trial are listed in Figure 4 and Table 5.
Danish: De vigtigste resultater fra studiet er vist i figur 4 og tabel 5.
English: They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation.
Danish: usædvanlig træthed eller svaghed, forvirring, koncentrationsbesvær, døsighed, overdreven sult, synsforstyrrelser, hovedpine, kvalme og hjertebanken.
English: Degradation of insulin degludec is similar to that of human insulin; all metabolites formed are inactive.
Danish: Nedbrydningen af insulin degludec er tilsvarende nedbrydningen af humant insulin.
English: Xultophy is administered as dose steps.
Danish: Xultophy administreres i dosistrin.
English: The key results of the trial are listed in Figure 3 and Table 4.
Danish: De vigtigste resultater fra studiet er vist i figur 3 og tabel 4.
English: One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide.
Danish: Et dosistrin indeholder 1 enhed insulin degludec og 0,036 mg liraglutid.
English: Instructions on how to use Xultophy 100 units/mL + 3.6 mg/mL solution for injection
Danish: Brugervejledning til Xultophy 100 enheder/ml + 3,6 mg/ml injektionsvæske, opløsning
English: • Press and hold down the dose button until the dose counter shows 0.
Danish: • Tryk på dosisknappen, og hold den nede, indtil dosistælleren viser
English: What Xultophy is and what it is used for What you need to know before you use Xultophy How to use Xultophy
Danish: Det skal du vide, før du begynder at bruge Xultophy Sådan skal du bruge Xultophy Bivirkninger
English: Eructation, flatulence
Danish: HbA1c vha. fraktiler.
English: INSTRUCTIONS ON USE
Danish: dosistrin valgt
English: Insulin degludec (units) Liraglutide (mg)
Danish: Insulin degludec (enh.)
English: Cholecystitis
Danish: Dosering
English: mg/dL
Danish: FPG mmol/l
English: Treatment is continued until the patient no longer benefits from it.
Danish: Behandlingen fortsættes, indtil patienten ikke længere har gavn af den.
English: The dose, which is given every 2 or 3 weeks, depends on the patient's body weight, the type of cancer being treated and what other cancer medicines are being used.
Danish: Den dosis, der gives hver anden eller tredje uge, afhænger af patientens kropsvægt, den behandlede kræfttype og hvilke andre kræftlægemidler, der anvendes.
English: The cancer responded to treatment in 45% of those given Zirabev (162 of 358 patients) and in 45% of those given Avastin (161 of 361).
Danish: Behandlingen virkede på kræften hos 45 % af de patienter, der fik Zirabev (162 ud af 358 patienter), og hos 45 % af dem, der fik Avastin (161 ud af 361 patienter).
English: The first infusion of Zirabev should last 90 minutes, but subsequent infusions may be given more quickly if the first infusion does not cause troublesome side effects.
Danish: Den første infusion af Zirabev bør vare 90 minutter, men de efterfølgende infusioner kan gives hurtigere, hvis den første ikke giver generende bivirkninger.
English: The doctor may decide to interrupt or stop treatment if the patient develops certain side effects.
Danish: Lægen kan beslutte at afbryde eller helt stoppe behandlingen af patienter, som får bestemte bivirkninger.
English: This means that Zirabev is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Danish: Det betyder, at Zirabev i høj grad svarer til et andet biologisk lægemiddel ("referencelægemidlet"), der allerede er godkendt i EU.
English: What measures are being taken to ensure the safe and effective use of Zirabev?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Zirabev?
English: As a result, the cancer cannot develop its own blood supply and cancer cells are starved of oxygen and nutrients, helping to slow down the growth of tumours.
Danish: Kræften kan følgelig ikke opretholde sin egen blodforsyning, og kræftcellerne får tilført for lidt ilt og for få næringsstoffer, hvilket er med til at hæmme væksten af tumorer.
English: By attaching to VEGF, Zirabev stops its effect.
Danish: Ved at binde sig til VEGF standser Zirabev dets virkning.
English: For more information about using Zirabev, see the package leaflet or contact your doctor or pharmacist.
Danish: For mere information om brug af Zirabev, se indlægssedlen eller kontakt lægen eller apotekspersonalet.
English: As for all medicines, data on the use of Zirabev are continuously monitored.
Danish: Som for alle lægemidler bliver data vedrørende brug af Zirabev løbende overvåget.
English: The reference medicine for Zirabev is Avastin.
Danish: Referencelægemidlet for Zirabev er Avastin.
English: Side effects reported with Zirabev are carefully evaluated and any necessary action taken to protect patients.
Danish: Bivirkninger rapporteret for Zirabev vurderes omhyggeligt, og der foretages nødvendige forholdsregler for at beskytte patienterne.
English: An overview of Zirabev and why it is authorised in the EU
Danish: En oversigt over Zirabev og hvorfor det er godkendt i EU
English: Other information about Zirabev
Danish: Andre oplysninger om Zirabev
English: The safety of Zirabev has been evaluated, and on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine Avastin.
Danish: Sikkerheden ved Zirabev er blevet vurderet, og på grundlag af alle de gennemførte studier anses bivirkningerne ved lægemidlet for at være sammenlignelige med bivirkningerne ved referencelægemidlet Avastin.
English: Zirabev is used in combination with other cancer medicines, depending on the nature of any previous treatments or the presence of mutations (genetic changes) in the cancer that affect how well particular medicines work.
Danish: Zirabev anvendes i kombination med andre kræftlægemidler afhængigt af arten af eventuelle tidligere behandlinger eller tilstedeværelsen af mutationer (genetiske forandringer) i kræften, der har indflydelse på, hvor godt bestemte lægemidler virker.
English: Zirabev contains the active substance bevacizumab and it is a ‘biosimilar medicine'.
Danish: Zirabev indeholder det aktive stof bevacizumab og er et "biosimilært" lægemiddel.
English: Zirabev received a marketing authorisation valid throughout the EU on 14 February 2019 Further information on Zirabev can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/zirabev.
Danish: Yderligere information om Zirabev findes på agenturets websted under: ema.europa.eu/medicines/human/EPAR/zirabev.
English: Zirabev can be used unless the cancer originates in particular cells called squamous cells;
Danish: Zirabev kan anvendes, medmindre kræften udløber fra bestemte celler kaldet pladeceller
English: Why is Zirabev authorised in the EU?
Danish: Hvorfor blev Zirabev godkendt i EU?
English: Because Zirabev is a biosimilar medicine, the studies on effectiveness and safety of bevacizumab carried out with Avastin do not all need to be repeated for Zirabev.
Danish: Da Zirabev er et biosimilært lægemiddel, behøver de studier af virkning og sikkerhed, der er udført for Avastin, ikke alle gentages for Zirabev.
English: Zirabev can only be obtained with a prescription and treatment should be supervised by a doctor who has experience in the use of cancer medicines.
Danish: Zirabev udleveres kun efter recept, og behandlingen bør overvåges af en læge med erfaring i brug af kræftlægemidler.
English: What is Zirabev and what is it used for?
Danish: Hvad er Zirabev, og hvad anvendes det til?
English: In addition, a study involving 719 patients with advanced non-small cell lung cancer showed that Zirabev was as effective as Avastin when given with the cancer medicines carboplatin and paclitaxel.
Danish: Derudover har et studie af 719 patienter med fremskreden ikkesmåcellet lungekræft vist, at Zirabev er lige så effektivt som Avastin, når det gives sammen med kræftlægemidlerne carboplatin og paclitaxel.
English: The active substance in Zirabev, bevacizumab, is a monoclonal antibody (a type of protein) that has been designed to attach to vascular endothelial growth factor (VEGF), a protein that circulates in the blood and encourages the growth of new blood vessels.
Danish: Det aktive stof i Zirabev, bevacizumab, er et monoklonalt antistof (en type protein), der er designet til at binde sig til proteinet vaskulær endotelial vækstfaktor (VEGF), som cirkulerer i blodet og fremmer væksten af nye blodkar.
English: Therefore, the Agency's view was that, as for Avastin, the benefits of Zirabev outweigh the identified risks and it can be authorised for use in the EU.
Danish: Agenturet var derfor af den opfattelse, at fordelene ved Zirabev opvejer de identificerede risici som for Avastin, og at det kan godkendes til anvendelse i EU.
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Zirabev has a highly similar structure, purity and biological activity to Avastin and is distributed in the body in the same way.
Danish: Det Europæiske Lægemiddelagentur konkluderede, at det i overensstemmelse med EU's krav til biosimilære lægemidler er påvist, at Zirabev har en struktur, renhed og biologisk aktivitet, der i høj grad svarer til Avastin, og at det fordeles i kroppen på samme måde.
English: Zirabev is a cancer medicine that is used to treat adults with the following cancers:
Danish: Zirabev er et lægemiddel til behandling af voksne med følgende kræfttyper:
English: Zirabev must not be used in people who are hypersensitive (allergic) to bevacizumab or any of the other ingredients, to Chinese hamster ovary cell products or other recombinant antibodies.
Danish: Zirabev må ikke anvendes af personer, der er overfølsomme (allergiske) over for bevacizumab eller andre af indholdsstofferne eller over for lægemidler med ovarieceller fra kinesiske hamstre eller andre rekombinante antistoffer.
English: What are the risks associated with Zirabev?
Danish: Hvilke risici er der forbundet med Zirabev?
English: Zirabev is given by infusion (drip) into a vein.
Danish: Zirabev gives ved infusion (drop) i en vene.
English: Laboratory studies comparing Zirabev with Avastin have shown that the active substance in Zirabev is highly similar to that in Avastin in terms of structure, purity and biological activity.
Danish: Laboratoriestudier, der sammenligner Zirabev med Avastin, har vist, at det aktive stof i Zirabev i meget høj grad svarer til Avastin med hensyn til struktur, renhed og biologisk aktivitet.
English: Studies have also shown that giving Zirabev produces similar levels of the active substance in the body to giving Avastin.
Danish: Der er også udført studier, der påviser, at Zirabev frembringer samme mængde aktivt stof i kroppen som behandling med Avastin.
English: • a lung cancer called non-small cell lung cancer when it is advanced or has spread or come back,
Danish: • en lungekræft kaldet ikkesmåcellet lungekræft, der er fremskreden, har spredt sig eller er vendt tilbage, og som ikke kan behandles ved operation.
English: In addition, a study in non-small cell lung cancer has shown that Zirabev's effectiveness is equivalent to that of Avastin in this condition.
Danish: Et studie af ikkesmåcellet lungekræft har desuden vist, at Zirabevs virkning svarer til Avastins til denne sygdom.
English: • cancer of the kidney (renal cell carcinoma) that is advanced or has spread elsewhere;
Danish: • nyrekræft (nyrecellekarcinom), der er fremskreden, eller som har spredt sig til andre steder
English: These data were considered sufficient to conclude that Zirabev will behave in the same way as Avastin in terms of effectiveness and safety in its authorised uses.
Danish: Disse oplysninger blev anset for tilstrækkelige til at konkludere, at Zirabevs sikkerhed og virkning svarer til Avastins ved de godkendte anvendelser.